Core Viewpoint - Universe Pharmaceuticals INC has successfully implemented a dual-class share structure, which will take effect on the Nasdaq Capital Market on February 13, 2026 [1]. Group 1: Dual-Class Share Structure - The company has amended and restated its memorandum and articles of association, changing its authorized share capital to US$20,000, divided into 1,800,000,000 Class A ordinary shares and 200,000,000 Class B ordinary shares, both with a par value of US$0.00001 each [2]. - The Class A Ordinary Shares will continue to trade under the symbol "UPC" and the same CUSIP number G9442G 138 starting from February 13, 2026 [3]. Group 2: Company Overview - Universe Pharmaceuticals INC is headquartered in Ji'an, Jiangxi, China, and specializes in the production and distribution of traditional Chinese medicine derivatives aimed at the elderly, addressing their physical conditions and promoting general well-being [4]. - The company also distributes biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements from third-party manufacturers, with products sold across 30 provinces in China [4].

Core Viewpoint - China SXT Pharmaceuticals, Inc. is launching an Artificial Intelligence Insight Initiative to enhance the application of AI and digital technologies in the Traditional Chinese Medicine (TCM) raw-material supply chain, aiming to improve supply chain transparency, operational stability, and quality oversight [1][3]. Group 1: AI Initiative Details - The company plans to utilize AI-supported analytical methods in key supply chain areas, including cultivation environment monitoring, origin and authenticity assessment, quality evaluation, and material grading [2]. - China SXT aims to explore AI's potential in supply-demand forecasting and circulation efficiency to support more consistent and data-informed supply chain management [2]. Group 2: Operational Goals - By enhancing digital analytics and process visibility across critical stages of the TCM raw-material supply chain, the company seeks to strengthen traceability, reinforce quality control, and support more reliable resource planning [3]. - The initiative aligns with the company's broader strategy of applying technology to improve overall operational management while preserving traditional TCM production principles [3]. Group 3: Leadership Perspective - Feng Zhou, Co-Chief Executive Officer, emphasized that applying AI to supply chain management is a crucial part of the company's long-term operational planning, aiming to enhance supply chain reliability and strengthen quality assurance capabilities [4].